PMX 53
Purity: ≥95%
Biological Activity
PMX 53 is a potent C5a receptor antagonist (IC50 = 20 nM). Also MrgX2 agonist. Stimulates MrgX2-mediated mast cell degranulation. Also inhibits C5a-induced hypernociception in rats, inhibits lung metastasis in a mouse breast cancer model and reduces atherosclerotic lesions in a mouse model of atherosclerosis.Negative Control also available.
Technical Data
(Modifications: Phe-1 = N-terminal Ac, X-2 = Orn, X-4 = D-Cha, Lactam bridge: Orn-2 to Arg-6)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Additional Information
Background References
-
Attenuation of cGVHD by C5a/C5aR blockade is associated with increased frequency of Treg
Y Wang, P Lai, X Chen, C He, X Huang, S Geng, C Luo, S Wu, W Ling, L Zhong, Z Lu, P Li, J Weng, X Du
Sci Rep, 2017;7(1):3603. -
PMX-53 as a dual CD88 antagonist and an agonist for Mas-related gene 2 (MrgX2) in human mast cells.
Subramanian et al.
Mol.Pharmacol., 2011;79:1005 -
Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice.
Manthey et al.
FASEB J, 2011;25:2447 -
Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice.
Kumar et al.
Sci.Rep., 2018;8:8101 -
Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory pain.
Ting et al.
Br.J.Pharmacol., 2008;153:1043 -
Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a.
Finch et al.
J.Med.Chem., 1999;42:1965 -
Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche.
Vadrevu et al.
Cancer Res., 2014;74:3454 -
Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer
TR Emmons, T Giridharan, KL Singel, ANH Khan, J Ricciuti, K Howard, SL Silva-Del, IL Debreceni, CEM Aarts, MC Brouwer, S Suzuki, TW Kuijpers, I Jongerius, LH Allen, VP Ferreira, A Schubart, H Sellner, J Eder, SM Holland, S Ram, JA Lederer, KH Eng, KB Moysich, K Odunsi, MB Yaffe, E Zsiros, BH Segal
Cancer Immunology Research, 2021;9(7):790-810.
Product Datasheets
Reconstitution Calculator
Molarity Calculator
Citations for PMX 53
The citations listed below are publications that use Tocris products. Selected citations for PMX 53 include:
4 Citations: Showing 1 - 4
-
Complement activation contributes to subretinal fibrosis through the induction of epithelial-to-mesenchymal transition (EMT) in retinal pigment epithelial cells.
Authors: Heping Et al.
J Neuroinflammation 2022;19:182
-
Epithelial phenotype restoring drugs suppress macular degeneration phenotypes in an iPSC model.
Authors: Sharma Et al.
Nat Commun 2021;12:7293
-
Gut Ischemia Reperfusion Injury Induces Lung Inflammation via Mesenteric Lymph-Mediated Neutrophil Activation.
Authors: Sarah Y Et al.
Front Immunol 2020;11:586685
-
Orthosteric and allosteric action of the C5a receptor antagonists.
Authors: Liu
Nat Struct Mol Biol 2018;25:472
FAQs
No product specific FAQs exist for this product, however you may
View all Peptide FAQsReviews for PMX 53
There are currently no reviews for this product. Be the first to review PMX 53 and earn rewards!
Have you used PMX 53?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image